Olmesartan medoxomil: Recent clinical and experimental acquisitions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 9, 2009, Pages 1149-1157

  Destro, Maurizio ^a   Preti, Paola ^b   D'Ospina, Antonio ^a   Achiri, Ngu Njwe Christian ^a   Ricci, Alessandra Rossi ^a   Cagnoni, Francesca ^a  

^a Medical Ward   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Angiotensin II; ARBs; Hypertension; Olmesartan; Therapeutic effects

Indexed keywords

OLMESARTAN; PLACEBO;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; HUMAN; HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 70349133987     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903203811     Document Type: Review

References (45)

1. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(Suppl):S21-32 (Pubitemid 32587656)
2. Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther 2004;26 (Suppl A):A21-7
3. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C
4. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-527 (Pubitemid 32381869)
5. von Bergmann K, Laeis P, Püchler K, et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19(Suppl):S33-40 (Pubitemid 32587657)
6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355(9204):637-645
7. Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007;151(7):952-962 (Pubitemid 47195538)
8. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma rennin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007;20(8):907-916
9. Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens 2004;17(8):690-695 (Pubitemid 39099176)
10. Fernandes-Santos C, de Souza Mendonça L, Mandarim-de-Lacerda CA. Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels 2009;24(3):219-227
11. Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(4):1135-1140 (Pubitemid 41710325)
12. Smith RD, Yokoyama H, Averill DB, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006;6(5):335-342 (Pubitemid 44749343)
13. Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007;1(2):97-106
14. Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008;26(3):583-588 (Pubitemid 351317269)
15. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17(6):425-432 (Pubitemid 36722208)
16. Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110(9):1103-1107 (Pubitemid 39319009)
17. Ogawa H, Kim-Mitsuyama S, Jinnouchi T, et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009:32(7);575-80
18. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003 (Pubitemid 34286536)
19. Viberti G, Nigel MW, for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in Ptients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation 2002;106:672-678
20. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-335
21. Berl T, Humsicker LG, Lewis JB, et al. Impact of achieved blood pressare on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-2179 (Pubitemid 41716450)
22. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-878 (Pubitemid 34940826)
23. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24(2):403-408 (Pubitemid 43348255)
24. Püchler K, Laeis P, Gunther A, et al. Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension [abstract no. P.11]. J Hum Hypertens 1999;13(Suppl 3):4
25. Masonson HN, Punzi HA, Neutel JM, et al. CS-866 (angiotensin II receptor antagonist): a double-blind study using ambulatory blood pressure monitoring in hypertensive patients [abstract no. D035]. Am J Hypertens 1998;11(4 Pt 2):77
26. Püchler K, Laeis P, Stumpe KO. A comparison of the efficacy and safety of the oral angiotensin II antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide [abstract no. P2.175]. J Hypertens 2001;19(Suppl 2):153
27. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(8A):37-43
28. Benicar® package insert. Sankyo Pharma, Inc, New York
29. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242
30. Kottke TE, Stroebel RJ, Hoffmann RS. JNC 7: it's more than high blood pressure. JAMA 2003;289(19):2573-2575
31. Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am J Health Syst Pharm 2000;57(1):51-54 (Pubitemid 30038915)
32. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improve patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors trough stable coronary artery disease). Circulation 2006;114(25):2850-2870 (Pubitemid 46018288)
33. Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005;22(1):32-43 (Pubitemid 40646918)
34. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurements in predicting mortality: the Dublin outcome Study. Hypertension 2005;46(1):156-161 (Pubitemid 40946507)
35. Pickering TG. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2(3):119-124 (Pubitemid 351699668)
36. van der Hoeven NV, van den Born BJ, Cammenga M, van Montfrans GA. Poor adherence to home blood pressure measurements schedule. J Hypertens 2009;27(2):275-279
37. Ferrario CM. Preferential effects of angiotensin receptor blocker (ARB) therapy on vascular structure: results of the Vascular Improvement with Olmesartan medoxomil Study (VIOS) [abstract no.SS1-2]. J Hypertens 2006;24(Suppl 6):414
38. Yokoyama H, Smith RD, Averill DB, et al. Vascular improvement with olmesartan medoxomil [abstract no. P-42]. Am J Hypertens 2005;18(5 Pt 2):23
39. Benicar® tablets (olmesartan medoxomil): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2006
40. Daiichi Sankyo UK Limited. Olmetec Plus flm-coated tablets: summary of product characyeristics [online]. Available from: http://emc.medicines.org.uk [Accessed 6 Mar 2006]
41. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonists. Am J Cardiol 2001;87(Suppl 8A):37-43
42. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001;19(Suppl 1):41-48 (Pubitemid 32587658)
43. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl A):28-32
44. Daiichi Sankyo UK Limited. Olmetec Plus flm-coated tablets: summary of product characyeristics [online]. Available from: http://emc.medicines.org.uk [Accessed 6 Mar 2007]
45. Benicar HCT tablets (olmesartan medoxomil - hydrochlorothiazide): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2006